Phase IV Validation Trial Opens: AI-Assisted Multimodal Imaging System for Prostate Cancer Diagnosis in PSA Gray Zone — What Clinicians Need to Know

References

1. 1.Australian Institute of Health and Welfare. (2024). Cancer in Australia 2024 (CAN-144). AIHW. https://www.aihw.gov.au/reports/cancer/cancer-in-australia-2024
2. 2.Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2024). Cancer statistics in China, 2024. CA: A Cancer Journal for Clinicians, 74(5), 398-424. https://doi.org/10.3322/caac.21834
3. 3.Guangxi Medical University. (2024). Prospective validation of an AI-assisted multimodal imaging-pathology fusion system for precision diagnosis and biopsy guidance in patients with suspected prostate cancer (NCT07631806). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07631806
4. 4.Loeb, S., Vellekoop, A., Ahmed, H. U., Catto, J., Emberton, M., Nam, R., Rosario, D. J., Scattoni, V., & Schoots, I. G. (2023). Systematic review of complications of prostate biopsy. European Urology, 84(2), 125-141. https://doi.org/10.1016/j.eururo.2023.03.023
5. 5.Sanda, M. G., Cadeddu, J. A., Kirkby, E., Chen, R. C., Crispino, T., Fontanarosa, J., Freedland, S. J., Greene, K., Klotz, L. H., Makarov, D. V., Nelson, J. B., Rodrigues, G., Sandler, H. M., Taplin, M. E., & Treadwell, J. R. (2024). Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Journal of Urology, 211(3), 533-542. https://doi.org/10.1097/JU.0000000000003497